- •Preface
- •Contents
- •Contributors
- •1: Living with Diabetic Retinopathy: The Patient’s View
- •My Patient Experience
- •Others’ Experiences
- •Photos of the Meaning of Diabetes
- •References
- •2: Diabetic Retinopathy Screening: Progress or Lack of Progress
- •Definitions of Screening for Diabetic Retinopathy
- •Studies Reporting the Prevalence of Diabetic Retinopathy
- •Reports on Blindness and Visual Impairment
- •Is There Evidence That Treatment for Sight-Threatening Diabetic Retinopathy Is Effective and Agreed Universally?
- •The Evidence That Diabetic Retinopathy Can Be Prevented or the Rate of Deterioration Reduced by Improved Control of Blood Glucose, Blood Pressure and Lipid Levels, and by Giving Up Smoking
- •The Evidence that Laser Treatment Is Effective
- •The Evidence That Vitrectomy for More Advanced Disease Is Effective
- •Progress of Lack of Progress in Screening for Diabetic Retinopathy in Different Parts of the World
- •References
- •3: Functional/Neural Mapping Discoveries in the Diabetic Retina: Advancing Clinical Care with the Multifocal ERG
- •Introduction
- •The Diabetes Epidemic
- •Current Treatment Focus
- •Vasculopathy and Neuropathy of the Retina
- •The Early Efforts
- •Some Breakthroughs
- •Predictive Models of Visible Retinopathy Onset at Specific Locations
- •How Is the mfERG Measured and What is it Measuring?
- •Where Are These Neural Signals Generated in the Retina?
- •Some Key Results
- •Adolescents and Adult Diabetes
- •Type 1 vs. Type 2: Differences in Retinal Function
- •References
- •4: Corneal Diabetic Neuropathy
- •Introduction
- •Corneal Confocal Microscopy
- •Corneal Nerves and Diabetes
- •Conclusion
- •References
- •5: Clinical Phenotypes of Diabetic Retinopathy
- •Natural History
- •MA Formation and Disappearance Rates
- •Alteration of the Blood–Retinal Barrier
- •Retinal Capillary Closure
- •Multimodal Macula Mapping
- •Clinical Retinopathy Phenotypes
- •Relevance for Clinical Trial Design
- •Relevance for Clinical Management
- •Targeted Treatments
- •References
- •6: Visual Psychophysics in Diabetic Retinopathy
- •Introduction
- •Visual Acuity
- •Color Vision
- •Contrast Sensitivity
- •Macular Recovery Function (Nyctometry)
- •Perimetry
- •Microperimetry (Fundus-Related Perimetry)
- •Conclusion
- •References
- •7: Mechanisms of Blood–Retinal Barrier Breakdown in Diabetic Retinopathy
- •The Protective Barriers of the Retina
- •The Inner and the Outer BRB
- •Inflammation and BRB Permeability
- •Leukocyte Mediators of Vascular Leakage
- •Other Mediators of Leukocyte Recruitment in DR
- •Structural Compromise of the BRB
- •Vascular Endothelial Growth Factor
- •Anti-VEGF Properties of Natriuretic Peptides
- •Proposed Model of BRB Breakdown in DR
- •Key Role of AZ in VEGF-Induced Leakage
- •Azurocidin Inhibition Prevents Diabetic Retinal Vascular Leakage
- •References
- •8: Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier
- •The Blood-Retinal Barrier
- •The Retinal Vascular Barrier
- •The Junctional Complex
- •ZO Proteins
- •Claudins
- •Junctional Adhesion Molecules
- •Occludin and Tricellulin
- •Vascular Permeability in Diabetic Retinopathy
- •VEGF-Induced Regulation of Endothelial Permeability
- •Occludin Phosphorylation and Permeability
- •Protein Kinase C in Regulation of Barrier Properties
- •Conclusions
- •References
- •9: Capillary Degeneration in Diabetic Retinopathy
- •Vascular Nonperfusion in Diabetes: Mechanisms
- •Molecular Causes of Capillary Degeneration
- •Unexplained Aspects of Diabetes-Induced Degeneration of Retinal Capillaries
- •What Is the Relation Between the Retinal Vasculature and Neuronal Retina Structure and Function in Diabetes?
- •Conclusion
- •References
- •10: Proteases in Diabetic Retinopathy
- •Proteases in Retinal Vasculature
- •Extracellular Proteases
- •Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Matrix Metalloproteinases
- •Endogenous Inhibitors of Proteases
- •Tissue Inhibitors of Metalloproteinases (TIMPs)
- •Plasminogen Activator Inhibitors (PAI)
- •Proteases in Retinal Neovascularization
- •Tissue Inhibitor of Matrix Metalloproteinases in Retinal Neovascularization
- •Inhibition of Retinal Angiogenesis by MMP Inhibitors
- •Inhibition of Retinal Angiogenesis by Inhibitors of the uPA/uPAR System
- •Proteases in Diabetic Macular Edema
- •Conclusion
- •References
- •11: Proteomics in the Vitreous of Diabetic Retinopathy Patients
- •Introduction
- •Vitreous Anatomy
- •A Candidate Approach
- •Proteomic Approaches
- •Vitreous Acquisition
- •Sample Pre-Fractionation
- •Mass Spectrometry
- •Spectral Analysis
- •Data Analysis
- •The Vitreous Proteome
- •2-DE-Based Proteomics
- •1-DE-Based Proteomics
- •Summary and Conclusions
- •References
- •12: Neurodegeneration in Diabetic Retinopathy
- •Introduction
- •Histological Evidence
- •Early Pathology Studies
- •Histological Evidence of Apoptosis
- •Gross Morphological Changes in the Retina
- •Reductions in Numbers of Surviving Amacrine Cells
- •Retinal Ganglion Cell Loss
- •Abnormalities in Ganglion Cell Morphology
- •Centrifugal Axon Abnormalities
- •Nerve Fiber Layer Thickness
- •Biochemical Evidence of Neurodegeneration and Cell Death
- •Functional Evidence of Neurodegenerative Changes
- •Electrophysiological Evidence for Neurodegeneration
- •Optic Nerve Retrograde Transport
- •Other Changes in Visual Function
- •Summary and Conclusions
- •References
- •13: Glucose-Induced Cellular Signaling in Diabetic Retinopathy
- •Introduction
- •Cellular Targets in DR
- •Endothelial Cell (EC) Dysfunction
- •Endothelial-Pericyte Interactions
- •Endothelial-Matrix Interactions
- •Signaling Mechanisms in DR
- •Altered Vasoactive Factors
- •Alteration of Metabolic Pathways
- •Polyol Pathway
- •Hexosamine Pathway
- •Protein Kinase C Pathway
- •Activation of Other Protein Kinases
- •Mitogen-Activated Protein Kinase (MAPK)
- •Increased Oxidative Stress
- •Protein Glycation
- •Aberrant Expression of Growth Factors
- •Transcription Factors
- •Transcription Regulators
- •Concluding Remarks
- •References
- •Introduction
- •The Growth-Hormone/Insulin-Like Growth Factor Pathway in Proliferative Retinopathies
- •Proliferative Diabetic Retinopathy (PDR)
- •Retinopathy of Prematurity (ROP)
- •Animal Models of Proliferative Retinopathies
- •IGFBP-3 as a Regulator of the Growth-Hormone/ Insulin-Like Growth Factor Pathway
- •Conclusion
- •References
- •15: Neurotrophic Factors in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Neurotrophic Factors
- •Neurotrophins and Others
- •Nerve Growth Factor
- •Glial-Cell-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Anti-angiogenic Neurotrophic Factors
- •Pigment-Epithelium-Derived Factor
- •SERPINA3K
- •Brain-Derived Neurotrophic Factor
- •Fibroblast Growth Factors
- •Insulin and Insulin-Like Growth Factor 1
- •Erythropoietin
- •Vascular Endothelial Growth Factor
- •Neurotrophic Factors and the Future of DR Research
- •References
- •16: The Role of CTGF in Diabetic Retinopathy
- •Introduction
- •ECM Remodeling and Wound Healing Mechanisms in Diabetic Retinopathy
- •ECM Remodeling in PCDR
- •Wound Healing Mechanisms in PDR
- •CTGF Structure and Function
- •CTGF in the Eye
- •CTGF in Ocular Fibrosis
- •CTGF in Ocular Angiogenesis
- •CTGF in Diabetic Retinopathy
- •CTGF in BL Thickening in PCDR
- •AGEs and CTGF in BL Thickening in PCDR
- •Role of VEGF in BL Thickening
- •BL Thickening in Diabetic CTGF-Knockout Mice
- •CTGF in PDR
- •Role of CTGF and VEGF in the “Angiofibrotic Switch” in PDR
- •Conclusions
- •References
- •17: Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema
- •Introduction
- •Pathogenesis of DME and Current Standard of Care
- •Ranibizumab for DME
- •Pegaptanib for DME
- •Bevacizumab for DME
- •VEGF Trap-Eye for DME
- •Other Considerations in the Management of DME
- •Combination Treatment for DME
- •DME and Quality of Life
- •Conclusions
- •References
- •18: Neurodegeneration, Neuropeptides, and Diabetic Retinopathy
- •Introduction
- •Neuropeptides Involved in the Pathogenesis of DR
- •Glutamate
- •Angiotensin II
- •Pigment Epithelial-Derived Factor
- •Somatostatin
- •Erythropoietin
- •Docosahexaenoic Acid and Neuroprotectin D1
- •Brain-Derived Neurotrophic Factor
- •Glial Cell Line-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Adrenomedullin
- •Concluding Remarks and Therapeutic Implications
- •References
- •19: Glial Cell–Derived Cytokines and Vascular Integrity in Diabetic Retinopathy
- •Introduction
- •The BRB Functional Unit Composed of Glial and Endothelial Cells
- •Tight Junctions Between Endothelial Cells Are Substantial Barrier of the BRB
- •Major Cytokines Derived from Glial Cells Affecting Tight Junctions of the BRB
- •VEGF
- •GDNF
- •APKAP12
- •A Possible Treatment of the Retinopathy with Retinoic Acid Analogues
- •Conclusion
- •References
- •20: Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
- •Introduction
- •What Are the Benefits and Risks of Reducing Blood Glucose?
- •On Average, 3 Years Was Required to Demonstrate the Beneficial Effect of Intensive Treatment
- •The Earlier in the Course of Diabetes That Intensive Therapy Is Initiated, Even Before the Onset of Retinopathy, the Greater the Long-Term Benefits
- •Risk Reduction in the Primary Prevention Cohort
- •Risk Reduction in the Secondary Prevention Cohort
- •There Was No Glycemic Threshold Regarding Progression of Retinopathy
- •Diabetic Ketoacidosis (DKA)
- •Efforts to Normalize Blood Glucose Are Associated with Weight Gain in People with Type 1 Diabetes
- •Connecting Peptide (C-Peptide) Responders Have Less Risk of Progression of Retinopathy
- •Effects of Improved Control on Retinopathy Were Sustained in the Long-Term
- •Quality of Life Measure
- •“Metabolic Memory”: A Phenomenon Producing a Long-Term Beneficial Influence of Early Metabolic Control on Clinical Outcomes
- •Need for a More Physiologic Glycemic Control Regimen
- •Effect of Intensive Insulin Therapy on Hypoglycemia Counterregulation
- •b Cell Function
- •Whole Pancreas Transplantation
- •Effect of SPK Transplantation on Diabetic Retinopathy
- •Islet Cell Transplantation
- •Adverse Effects of Chronic Immunosuppression
- •Effect of Islet Cell Transplantation on Retinopathy
- •References
- •Index
96 |
Midena and Vujosevic |
CONCLUSION
Diabetes has a relevant impact on visual function, up to permanent visual acuity loss when retinopathy is clinically evident, but changes in visual function may occur long before any structural change is detected by experienced fundus examination or even by fluorescein angiography. Visual function abnormalities in diabetes, mainly detected and quantified using psychophysical tests, should therefore be viewed as a new way of detecting and quantifying diabetic retinopathy and evaluating any old or new treatment approach.
REFERENCES
1. Bresnick GH. Diabetic retinopathy viewed as a neurosensory disorder. Arch Ophthalmol. 1986;104:989–90.
2. Midena E. Fundus perimetry-microperimetry: an introduction. In: Midena E, editor. Perimetry and the fundus: an introduction to microperimetry. Thorofare, NJ: Slack Incorporated; 2006. p. 1–7.
3. Hyvärinen L, Laurinen P, Rovamo J. Contrast sensitivity in evaluation of visual impairment due to diabetes. Acta Ophthalmol. 1983;61:94–101.
4. Sharma S, Oliver-Fernandez A, Liu W, et al. The impact of diabetic retinopathy on healthrelated quality of life. Curr Opin Ophthalmol. 2005;16:155–9.
5. Owsley C, Sloane ME. Contrast sensitivity, acuity, and the perception of ‘real-world’ targets. Br J Ophthalmol. 1987;71:791–6.
6. Midena E, editor. Perimetry and the fundus: an introduction to microperimetry. Thorofare, NJ: Slack Incorporated; 2006.
7. Gibson RA, Sanderson HF. Observer variation in ophthalmology. Br J Ophthalmol. 1980;64:457–60.
8. Wick B, Schor CM. A comparison of the Snellen chart and the S-chart for visual acuity assessment in amblyopia. J Am Optom Assoc. 1984;55:359–61.
9. Lovie-Kitchin JE. Validity and reliability of visual acuity measurements. Ophthalmic Physiol Opt. 1988;8:363–70.
10. Kniestedt C, Stamper RL. Visual acuity and its measurement. Ophthalmol Clin North Am. 2003;16:155–70.
11. Pandit JC. Testing acuity of vision in general practice: reaching recommended standard. BMJ. 1994;309:1408.
12. Currie Z, Bhan A, Pepper I. Reliability of Snellen charts for testing visual acuity for driving: prospective study and postal questionnaire. BMJ. 2000;321:990–2.
13. Raasch TW, Bailey IL, Bullimore MA. Repeatability of visual acuity measurement. Optom Vis Sci. 1998;75:342–8.
14. Bailey IL, Lovie JE. New design principles for visual acuity letter charts. Am J Optom Physiol Opt. 1976;53:740–5.
15. Ferris III FL, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91–6.
16. Sloan LL. New test charts for the measurement of visual acuity at far and near distances. Am J Ophthalmol. 1959;48:807–13.
17. Elliott DB, Sheridan M. The use of accurate visual acuity measurements in clinical anticataract formulation trials. Ophthalmic Physiol Opt. 1988;8:397–401.
18. Hudson C, Flanagan JG, Turner GS, et al. Correlation of a scanning laser derived oedema index and visual function following grid laser treatment for diabetic macular oedema. Br J Ophthalmol. 2003;87:455–61.
Visual Psychophysics in Diabetic Retinopathy |
97 |
19. Ang GS, Vusirikala B, Mukherji S, et al. Visual acuity and diabetic maculopathy. Ann Ophthalmol. 2006;38:305–10.
20. Sakata K, Funatsu H, Harino S, et al. Relationship of macular microcirculation and retinal thickness with visual acuity in diabetic macular edema. Ophthalmology. 2007;114:2061–9.
21. Early Treatment Diabetic Retinopathy Study Research Group. hotocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.
22. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127:688–9.
23. Bandello F, Polito A, Del Borrello M, et al. “Light” versus “classic” laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol. 2005;89:864–70.
24. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–7.
25. Laursen ML, Moeller F, et al. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol. 2004;8:1173–9.
26. Massin P, Duguid G, Erginay A, et al. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol. 2003;135:169–77.
27. Diabetic Retinopathy Clinical Research Network; Browning DJ, Glassman AR, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114:525–36.
28. Browning DJ, Apte RS, Bressler SB, et al. Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. Retina. 2009;29:300–5.
29. Lakowski R, Aspinall PA, Kinnear PR. Association between colour vision losses and diabetes mellitus. Ophthalmol Res. 1972;4:145–59.
30. Hardy KJ, Scase MO, Foster DH, et al. Effect of short term changes in blood glucose on visual pathway function in insulin dependent diabetes. Br J Ophthalmol. 1995;79:38–41.
31. Boulton AJ, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 1990;33:431–7.
32. Florkowski CM, Rowe BR, Nightingale S, et al. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes. 1991;40:129–33.
33. Julu PO. Essential fatty acids prevent slowed nerve conduction in streptozotocin diabetic rats. J Diabet Complications. 1988;2:185–8.
34. Tomlinson DR, Robinson JP, Compton AM, et al. Essential fatty acid treatment—effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats. Diabetologia. 1989;32:655–9.
35. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med. 1990;7:319–23.
36. Dean FM, Arden GB, Dornhorst A. Partial reversal of protan and tritan colour defects with inhaled oxygen in insulin dependent diabetic subjects. Br J Ophthalmol. 1997;81:27–30.
37. Roy MS, Gunkel RD, Podgor MJ. Color vision defects in early diabetic retinopathy. Arch Ophthalmol. 1986;104:225–8.
38. Farnsworth D, editor. The Farnsworth-Munsel 100 Hue Test manual. Baltimore, MD: Munsel Color Co; 1957.
39. Francois J, Verriest G. Acquired dyschromatopsias. Ann Ocul. 1957;190:713–46.
40. Zanen J. Introduction a l’etude de dyschromatopsias retin-iennes contrales asquises. Bull Soc Belge Ophtalmol. 1953;103:3–148.
41. Bresnick GH, Condit RS, Palta M, et al. Association of hue discrimination loss and diabetic retinopathy. Arch Ophthalmol. 1985;103:1317–24.
98 |
Midena and Vujosevic |
42. Aspinall PA, Kinnear PR, Duncan LJ. Prediction of diabetic retinopathy from clinical variables and color vision data. Diabetes Care. 1983;6:144–8.
43. Kessel L, Alsing A, Larsen M. Diabetic versus non-diabetic colour vision after cataract surgery. Br J Ophthalmol. 1999;83:1042–5.
44. Kinnear PR, Aspinall PA, Lakowski R. The diabetic eye and colour vision. Trans Ophthalmol Soc U K. 1972;92:69–78.
45. Volbrecht VJ, Schneck ME, Adams AJ, et al. Diabetic short-wavelength sensitivity: variations with induced changes in blood glucose level. Invest Ophthalmol Vis Sci. 1994;35:1243–6.
46. Cho NC, Poulsen GL, Ver Hoeve JN. Selective loss of S-cones in diabetic retinopathy. Arch Ophthalmol. 2000;118:1393–400.
47. Friström B. Peripheral and central colour contrast sensitivity in diabetes. Acta Ophthalmol Scand. 1998;76:541–5.
48. North RV, Farrell U, Banford D, et al. Visual function in young IDDM patients over 8 years of age. A 4-year longitudinal study. Diabetes Care. 1997;20:1724–30.
49. Malagola R, Gargiulo P, Giusti C, et al. Screening of early colour vision defects in insulin dependent diabetic patients with background retinopathy. Invest Ophthalmol Vis Sci. 1994;35:1593.
50. Tregear SJ, Knowles PJ, Ripley LG, et al. Chromatic-contrast threshold impairment in diabetes. Eye. 1997;11:537–46.
51. Ewing FM, Deary IJ, Strachan MW, et al. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev. 1998;19:462–76.
52. Yamamoto S, Kamiyama M, Nitta K, et al. Selective reduction of the S cone electroretinogram in diabetes. Br J Ophthalmol. 1996;80:973–5.
53. Crognale MA, Switkes E, Rabin J, et al. Application of the spatiochromatic visual evoked potential to detection of congenital and acquired color-vision deficiencies. J Opt Soc Am A Opt Image Sci Vis. 1993;10:1818–25.
54. Roy MS, McCulloch C, Hanna AK, et al. Colour vision in long-standing diabetes mellitus. Br J Ophthalmol. 1984;68:215–7.
55. Hardy KJ, Lipton J, Scase MO, et al. Detection of colour vision abnormalities in uncomplicated type 1 diabetic patients with angiographically normal retinas. Br J Ophthalmol. 1992;76:461–4.
56. Kurtenbach A, Flögel W, Erb C. Anomaloscope matches in patients with diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2002;240:79–84.
57. Verrotti A, Lobefalo L, Chiarelli F, et al. Colour vision and persistent microalbuminuria in children with type-1 (insulin-dependent) diabetes mellitus: a longitudinal study. Diabetes Res Clin Pract. 1995;30:125–30.
58. Kurtenbach A, Schiefer U, Neu A, et al. Preretinopic changes in the colour vision of juvenile diabetics. Br J Ophthalmol. 1999;83:43–6.
59. Kurtenbach A, Schiefer U, Neu A, et al. Development of brightness matching and colour vision deficits in juvenile diabetics. Vision Res. 1999;39:1221–9.
60. Giusti C. Lanthony 15-Hue desaturated test for screening of early color vision defects in uncomplicated juvenile diabetes. Jpn J Ophthalmol. 2001;45:607–11.
61. Hardy KJ, Fisher C, Heath P, et al. Comparison of colour discrimination and electroretinography in evaluation of visual pathway dysfunction in aretinopathic IDDM patients. Br J Ophthalmol. 1995;79:35–7.
62. Fong DS, Barton FB, Bresnick GH. Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. Am J Ophthalmol. 1999;128:612–7.
Visual Psychophysics in Diabetic Retinopathy |
99 |
63. Green FD, Ghafour IM, Allan D, et al. Colour vision of diabetics. Br J Ophthalmol. 1985;69:533–6.
64. Maár N, Tittl M, Stur M, et al. A new colour vision arrangement test to detect functional changes in diabetic macular oedema. Br J Ophthalmol. 2001;85:47–51.
65. Ong GL, Ripley LG, Newsom RSB, et al. Assessment of colour vision as a screening test for sight threatening diabetic retinopathy before loss of vision. Br J Ophthalmol. 2003;87: 747–52.
66. Ong GL, Ripley LG, Newsom RS, Cooper M, et al. Screening for sight-threatening diabetic retinopathy: comparison of fundus photography with automated color contrast threshold test. Am J Ophthalmol. 2004;137:445–52.
67. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007;27:816–24.
68. Di Leo MA, Caputo S, Falsini B, et al. Nonselective loss of contrast sensitivity in visual system testing in early type I diabetes. Diabetes Care. 1992;15:620–5.
69. Trick GL, Burde RM, Gordon MO, et al. The relationship between hue discrimination and contrast sensitivity deficits in patients with diabetes mellitus. Ophthalmology. 1988;95:693–8.
70. Brinchmann-Hansen O, Bangstad HJ, Hultgren S, et al. Psychophysical visual function, retinopathy, and glycemic control in insulin-dependent diabetics with normal visual acuity. Acta Ophthalmol. 1993;71:230–7.
71. Ghafour IM, Foulds WS, Allan D, et al. Contrast sensitivity in diabetic subjects with and without retinopathy. Br J Ophthalmol. 1982;66:492–5.
72. Della Sala S, Bertoni G, Somazzi L, et al. Impaired contrast sensitivity in diabetic patients with and without retinopathy: a new technique for rapid assessment. Br J Ophthalmol. 1985;69:136–42.
73. Sokol S, Moskowitz A, Skarf B, et al. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol. 1985;103:51–4.
74. Maione M, Cordella M, Franchi A, et al. Contrast sensitivity in diabetics: comparison between psychophysical and evoked potential methods. Ann Oftalmol Clin Ocul. 1986;6:445–52.
75. Arend O, Remky A, Evans D, et al. Contrast sensitivity loss is coupled with capillary dropout in patients with diabetes. Invest Ophthalmol Vis Sci. 1997;38:1819–24.
76. Midena E, Segato T, Bottin G, et al. The effect on the macular function of laser photocoagulation for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 1992;230:162–5.
77. Talwar D, Sharma N, Pai A, et al. Contrast sensitivity following focal laser photocoagulation in clinically significant macular oedema due to diabetic retinopathy. Clin Experiment Ophthalmol. 2001;29:17–21.
78. Farahvash MS, Mahmoudi AH, Farahvash MM, et al. The impact of macular laser photocoagulation on contrast sensitivity function in patients with clinically significant macular edema. Arch Iran Med. 2008;11:143–7.
79. Midena E, Segato T, Giuliano M, et al. Macular recovery function (nyctometry) in diabetics without and with early retinopathy. Br J Ophthalmol. 1990;74:106–8.
80. Gliem H, Schulze DP. Initial phase of dark adaptation, sensibility to dazzling and diabetic retinopathy. Klin Monbl Augenheilkd. 1975;166:766–9.
81. Simonsen SE. The value of the oscillatory potential in selecting juvenile diabetics at risk of developing proliferative retinopathy. Acta Ophthalmol. 1980;58:865–78.
82. Frost-Larsen K, Larsen HW. Macular recovery time recorded by nyctometry—a screening method for selection of patients who are at risk of developing proliferative diabetic retinopathy. Results of a 5-year follow-up. Acta Ophthalmol Suppl. 1985;173:39–47.
83. Frost-Larsen K, Larsen HW, Simonsen SE. Oscillatory potential and nyctometry in insulindependent diabetics. Acta Ophthalmol. 1980;58:879–88.
100 |
Midena and Vujosevic |
84. Verrotti A, Lobefalo L, Chiarelli F, et al. Macular recovery time in diabetic children without retinopathy. Diabetes Res Clin Pract. 1996;32:149–55.
85. Lauritzen T, Frost-Larsen K, Larsen HW, et al. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet. 1983;1:200–4.
86. Frost-Larsen K, Lund-Anderson C, Starup K. Macular recovery during onset and development of diabetic retinopathy in childhood and adolescence. Acta Ophthalmol (Copenh). 1989;67:401–4.
87. Frost-Larsen K, Larsen HW, Simonsen SE. Value of electroretinography and dark adaptation as prognostic tools in diabetic retinopathy. Dev Ophthalmol. 1981;2:222–34.
88. Virsu V. Retinal mechanisms of visual adaptation and afterimages. Med Biol. 1978;56: 84–96.
89. Dowling JE. The site of visual adaptation. Science. 1967;155:273–9.
90. Trick GL, Trick LR, Kilo C. Visual field defects in patients with insulin-dependent and noninsulin-dependent diabetes. Ophthalmology. 1990;97:475–82.
91. Chee CK, Flanagan DW. Visual field loss with capillary non-perfusion in preproliferative and early proliferative diabetic retinopathy. Br J Ophthalmol. 1993;77:726–30.
92. Henricsson M, Heijl A. Visual fields at different stages of diabetic retinopathy. Acta Ophthalmol. 1994;72:560–9.
93. Bek T, Lund-Andersen H. Cotton-wool spots and retinal light sensitivity in diabetic retinopathy. Br J Ophthalmol. 1991;75:13–7.
94. Zwas F, Weiss H, McKinnon P. Spectral sensitivity measurements in early diabetic retinopathy. Ophthalmic Res. 1980;12:87–96.
95. Adams AJ, Zisman F, Ai E, Bresnick G. Macular edema reduced B cone sensitivity in diabetics. Appl Opt. 1987;26:1455–7.
96. Greenstein V, Sarter B, Hood D. Hue discrimination and S cone pathway sensitivity in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1990;31:1008–14.
97. Greenstein VC, Shapiro A, Zaidi Q. Psychophysical evidence for post-receptoral sensitivity loss in diabetics. Invest Ophthalmol Vis Sci. 1992;33:2781–90.
98. Remky A, Arend O, Hendricks S. Short-wavelength automated perimetry and capillary density in early diabetic maculopathy. Invest Ophthalmol Vis Sci. 2000;41:274–81.
99. Hudson C, Flanagan JG, Turner GS, et al. Short-wavelength sensitive visual field loss in patients with clinically significant diabetic macular edema. Diabetologia. 1998;41:918–28.
100. Lobefalo L, Verrotti A, Mastropasqua L, et al. Blue-on-yellow and achromatic perimetry in diabetic children without retinopathy. Diabetes Care. 1998;21:2003–6.
101. Agardh E, Stjernquist H, Heijl A, et al. Visual acuity and perimetry as measures of visual function in diabetic macular oedema. Diabetologia. 2006;49(1):200–6.
102. Bengtsson B, Heijl A, Agardh E. Visual fields correlate better than visual acuity to severity of diabetic retinopathy. Diabetologia. 2005;48:2494–500.
103. Sunness JS, Schuchard RA, Shen N, et al. Landmark-driven fundus perimetry using the scanning laser ophthalmoscope. Invest Ophthalmol Vis Sci. 1995;36:1863–74.
104.Vujosevic S, Midena E, Pilotto E, et al. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci. 2006;47:3044–51.
105. Midena E, Radin PP, Pilotto E, et al. Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A microperimetry study. Semin Ophthalmol. 2004;19:55–61.
106. Midena E, Vujosevic S, Convento E, et al. Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration. Br J Ophthalmol. 2007;91: 1499–503.
Visual Psychophysics in Diabetic Retinopathy |
101 |
107. Rohrschneider K, Springer C, Bültmann S, et al. Microperimetry—comparison between the micro perimeter 1 and scanning laser ophthalmoscope—fundus perimetry. Am J Ophthalmol. 2005;139:125–34.
108. Midena E, Vujosevic S, Cavarzeran F; for the Microperimetry Study Group. Normative age-related database for the MP1 microperimeter. Ophthalmology. 2010;117(8):1571–6.
109. Mori F, Ishiko S, Kitaya N, et al. Scotoma and fixation patterns using scanning laser ophthalmoscope microperimetry in patients with macular dystrophy. Am J Ophthalmol. 2001;132:897–902.
110. Rohrschneider K, Bültmann S, Glück R, et al. Scanning laser ophthalmoscope fundus perimetry before and after laser photocoagulation for clinically significant diabetic macular edema. Am J Ophthalmol. 2000;129:27–32.
111. Mori F, Ishiko S, Kitaya N, et al. Use of scanning laser ophthalmoscope microperimetry in clinically significant macular edema in type 2 diabetes mellitus. Jpn J Ophthalmol. 2002;46:650–5.
112. Rohrschneider K, Glück R, Becker M, et al. Scanning laser fundus perimetry before laser photocoagulation of well defined choroidal neovascularisation. Br J Ophthalmol. 1997;81:568–73.
113. Sunness JS, Applegate CA, Haselwood D, et al. Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. Ophthalmology. 1996;103:1458–66.
114. Kube T, Schmidt S, Toonen F, et al. Fixation stability and macular light sensitivity in patients with diabetic maculopathy: a microperimetric study with a scanning laser ophthalmoscope. Ophthalmologica. 2005;219:16–20.
115. Loewenstein A, Sunness JS, Bressler NM, et al. Scanning laser ophthalmoscope fundus perimetry after surgery for choroidal neovascularization. Am J Ophthalmol. 1998;125: 657–65.
116. Midena E. Psychophysical investigations in myopia. In: Midena E, editor. Myopia and related diseases. New York, NY: Ophthalmic Communications Society; 2005. p. 120–4.
117. Varano M, Parisi V, Tedeschi M, et al. Macular function after PDT in myopic maculopathy: psychophysical and electrophysiological evaluation. Invest Ophthalmol Vis Sci. 2005;46:1453–62.
118. Okada K, Yamamoto S, Mizunoya S, et al. Correlation of retinal sensitivity measured with fundus-related microperimetry to visual acuity and retinal thickness in eyes with diabetic macular edema. Eye. 2006;20:805–9.
119. Vujosevic S, Pilotto E, Bottega E, et al. Retinal fixation impairment in diabetic macular edema. Retina. 2008;28:1443–50.
120. Møller F, Bek T. The relation between visual acuity, fixation stability, and the size and location of foveal hard exudates after photocoagulation for diabetic maculopathy: a 1-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2003;241:458–62.
121. Møller F, Laursen ML, Sjølie AK. Binocular fixation topography in patients with diabetic macular oedema: possible implications for photocoagulation therapy. Graefes Arch Clin Exp Ophthalmol. 2005;243:903–10.
122. Carpineto P, Ciancaglini M, Di Antonio L, et al. Fundus microperimetry patterns of fixation in type 2 diabetic patients with diffuse macular edema. Retina. 2007;27:21–9.
123. Vujosevic S, Midena E. Diabetic retinopathy. In: Midena E, editor. Perimetry and the fundus: an introduction to microperimetry. Thorofare, NJ: Slack Incorporated; 2006. p. 177–9.
124. Vujosevic S, Bottega E, Casciano M, et al. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010;30:908–16.
102 |
Midena and Vujosevic |
125. Verriest G, Van Laethem J, Uvijls A. A new assessment of the normal ranges of the Farns- worth-Munsell 100-hue test scores. Am J Ophthalmol. 1982;93:635–42.
126. Wong R, Khan J, Adewoyin T, et al. The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study. BMC Ophthalmol. 2008;17:8–15.
127. Virsu V, LehtiG P, Rovamo J. Contrast sensitivity in normal and pathological vision. Doc Ophthalmol Proc Ser.1981;30:263–272.
128. Regan D, Neima D. Low-contrast letter charts in early diabetic retinopathy, ocular hypertension, glaucoma, and Parkinson’s disease. Br J Ophthalmol. 1984;68:885–9.
129. Khosla PK, Talwar D, Tewari HK. Contrast sensitivity changes in background diabetic retinopathy. Can J Ophthalmol. 1991;26:7–11.
130. Bangstad HJ, Brinchmann-Hansen O, Hultgren S,, et al. Impaired contrast sensitivity in adolescents and young type 1 (insulin-dependent) diabetic patients with microalbuminuria. Acta Ophthalmol (Copenh). 994;72:668–73.
131. De Marco R, Capasso L, Magli A, et al. Measuring contrast sensitivity in aretinopathic patients with Insulin Dependent Diabetes Mellitus. Doc Ophthalmol. 1996–1997;93:199–209.
132. Verrotti A, Lobefalo L, Petitti MT, et al. Relationship between contrast sensitivity and metabolic control in diabetics with and without retinopathy. Ann Med. 1998;30:369–74.
133. Mackie SW, Walsh G. Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation. Ophthalmic Physiol Opt. 1998;18:173–81.
134. Lövestam-Adrian M, Svendenius N, Agardh E. Contrast sensitivity and visual recovery time in diabetic patients treated with panretinal photocoagulation. Acta Ophthalmol Scand. 2000;78:672–6.
135. Stavrou EP, Wood JM. Letter contrast sensitivity changes in early diabetic retinopathy. Clin Exp Optom. 2003;86:152–6.
136. Bek T, Lund-Andersen H. Localised blood-retinal barrier leakage and retinal light sensitivity in diabetic retinopathy. Br J Ophthalmol. 1990;74:388–92.
137.Lutze M, Bresnick GH. Lens-corrected visual field sensitivity and diabetes. Invest Ophthalmol Vis Sci. 1994;35:649–55.
138.Nomura R, Terasaki H, Hirose H, et al. Blue-on-yellow perimetry to evaluate S cone sensitivity in diabetics. Ophthalmic Res. 2000;32:69–72.
139. Verrotti A, Lobefalo L, Altobelli E, et al. Static perimetry and diabetic retinopathy: a longterm follow-up. Acta Diabetol. 2001;38:99–105.
140. Afrashi F, Erakgün T, Köse S, et al. Blue-on-yellow perimetry versus achromatic perimetry in type 1 diabetes patients without retinopathy. Diabetes Res Clin Pract. 2003;61:7–11.
141. Remky A, Weber A, Hendricks S, et al. Short-wavelength automated perimetry in patients with diabetes mellitus without macular edema. Graefes Arch Clin Exp Ophthalmol. 2003;241:468–71.
142. Han Y, Adams AJ, Bearse MA Jr, et al. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol. 2004;122:1809–15.
143. Nitta K, Saito Y, Kobayashi A, et al. Influence of clinical factors on blue-on-yellow perimetry for diabetic patients without retinopathy: comparison with white-on-white perimetry. Retina. 2006;26:797–802.
144. Pahor D. Automated static perimetry as a screening method for evaluation of retinal perfusion in diabetic retinopathy. Int Ophthalmol. 1997–1998;21:305–9.
145. Moller F, Bek T. The relation between visual acuity, fixation stability, and the size and location of foveal hard exudates after photocoagulation for diabetic maculopathy: a 1-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2003;241:458–62.
Visual Psychophysics in Diabetic Retinopathy |
103 |
146. Unoki N, Nishijima K, Sakamoto A, et al. Retinal sensitivity loss and structural disturbance in areas of capillary nonperfusion of eyes with diabetic retinopathy. Am J Ophthalmol. 2007;144:755–760.
147. Grenga P, Lupo S, Domanico D, et al. Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema: a microperimetry and optical coherence tomography study. Retina. 2008;28:1270–5.